-
-
-
-
-
-
-
Denali shares clinical data on enzyme treatments for rare diseases
-
-
-
-
-
-
-
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
-
-
-
-
-
-
15,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

